Antibody-Drug Conjugates: Cancer Therapies to Watch
There are up to 80 ADCs in clinical development with close to 600 ongoing trials.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
Bavencio Approved for First-Line Urothelial Carcinoma Maintenance Treatment
The FDA has approved Bavencio® (avelumab; EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Can Advocacy Groups Provide Useful Patient-Centered Data?
A survey presented during ASCO20 found that patients who considered themselves adequately informed felt “in control” most days.
Study: Template-Based LND May Aid Local UTUC Control
Template-based lymph node dissection in patients with upper tract urothelial carcinoma could facilitate better local disease control by eliminating micrometastasis, according to investigators.
Positive vs Negative Lymph Nodes Portend Worse Prognosis in Stage 3 RCC
In a study involving stage 3 RCC patients, those with positive lymph nodes had markedly inferior 5-year survival compared with those with lymph-node negative disease and 5-year survival similar to those with stage 4 RCC.
Antitumor Activity Reported With Lenvatinib/Pembrolizumab in Metastatic RCC After Disease Progression on ICI Therapy
Lenvatinib plus pembrolizumab resulted in antitumor activity in patients with metastatic clear cell RCC that progressed during or after treatment with an immune checkpoint inhibitor, according to phase 2 results.
Phase 3 PROSPER RCC Trial to Evaluate Neoadjuvant/Adjuvant Immunotherapy in Nonmetastatic RCC
The phase 3 PROSPER RCC trial will evaluate neoadjuvant with adjuvant nivolumab among patients with nonmetastatic RCC compared with surgery and standard-of-care surveillance.
Tivozanib Superior to Sorafenib in Heavily Pretreated Renal Cell Carcinoma
Tivozanib resulted in superior PFS compared with sorafenib among patients with RCC that progressed on 2 or 3 prior systemic regimens, including another VEGF inhibitor, according to the final analysis of the TIVO-3 trial.
Response-Based Addition of Ipilimumab to Nivolumab Not Effective in RCC
The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in few responses among patients who did not achieve a response with nivolumab alone, according to results of a phase 2 trial.
HIF-2α Inhibitor Demonstrates Promising Activity Against VHL-Associated RCC
A HIF-2α inhibitor demonstrated antitumor activity against VHL-associated clear cell RCC and other associated tumors, according to interim results of a phase 2 study.
Nivolumab Plus Ipilimumab Demonstrated Promising Activity in Previously ICI-Treated RCC
Preliminary phase 2 data suggest that nivolumab plus ipilimumab was efficacious in advanced RCC that previously progressed with immune checkpoint inhibitor therapy.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Avelumab Shown to Prolong Survival in Advanced Urothelial Carcinoma
Adding avelumab to best supportive care following chemo in advanced UC significantly improved OS compared with best supportive care alone.
Pembrolizumab-Axitinib Continued to Offer Durable Benefits in Advanced RCC
Updated findings from KEYNOTE-426 showed that frontline pembrolizumab-axitinib continued to be associated with improved PFS and OS compared with sunitinib in advanced RCC.
Savolitinib Shows “Encouraging Efficacy” in MET-Driven Papillary RCC
Savolitinib vs sunitinib demonstrated numerically better PFS, OS, and safety among patients with MET-driven papillary renal cell carcinoma.
Prioritizing Urologic Cancer Cases During the COVID-19 Pandemic
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Pathologic Stage at RNU Predicts Oncologic Outcomes in High-Grade UTUC
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?
Initial data from a phase 1b trial shows encouraging results.
5-ARIs Do Not Lower Bladder Cancer Risk
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
